Leqembi is an antibody that reduces the number of beta-amyloid plaques in people with early-stage Alzheimer's. The drug helps slow down memory loss.
A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler, under-the-skin injection is equally effective as the currently approved intravenous infusion, according to study results presented Wednesday by its maker, Eisai.But hopes that the subcutaneo...
Meeks received her first infusion of Leqembi in September 2023 after overcoming a few logistical hurdles, such as securing an appointment with a neurologist and getting insurance to cover the costly treatment, which it initially denied because of her age. Since then, she has been taking infusion...
Nikhil Palekar, MD:The FDA did approve Leqembi, but also it did have a blackbox warning along with the approval. That blackbox warning clearly states the increased risk of a potentially dangerous side effect called ARIA, which basically causes brain s...